Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Pharmaceutical And Life Sciences Real World Evidence Market Poised To Hit $5.6 Billion By 2030 With A 11.9% CAGR
The pharmaceutical and life sciences real world evidence market has experienced significant growth in recent years. This market is anticipated to expand from $3.2 billion in 2025 to $3.57 billion in 2026, with a compound annual growth rate (CAGR) of 11.7%. Historically, this expansion has been propelled by the increasing integration of electronic health records, an intensified focus on drug safety monitoring, the development of patient registries, a growing need for evidence-based decision making, and an uptick in pharmaceutical research and development investments.
The pharmaceutical and life sciences real world evidence market size is projected to experience substantial growth in the coming years. It is forecast to grow to $5.6 billion in 2030, achieving a compound annual growth rate (CAGR) of 11.9%. The expansion during the forecast period is attributable to the integration of AI-driven analytics, the proliferation of RWE platforms and dashboards, the adoption of predictive modeling tools, increased collaboration between payers and pharma entities, and the rising prominence of real-world evidence in personalized medicine. Prominent trends anticipated for this period involve the integration of various real-world data sources, predictive modeling for drug outcomes, the generation of patient-centric evidence, optimized regulatory compliance, and the application of advanced analytics for market access.
Get A Free Sample Report With In-Depth Market Insights:
Pharmaceutical And Life Sciences Real World Evidence Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing need for personalized medicine is anticipated to drive expansion in the pharmaceutical and life sciences real-world evidence market moving ahead. This approach, known as personalized medicine, tailors healthcare and therapeutic interventions according to an individual patient’s distinct biological and personal attributes. Its adoption is on the rise, attributed to breakthroughs in genomic technologies that empower healthcare providers to rapidly and precisely analyze a patient’s genetic data, thereby facilitating more precise and impactful treatments. Within pharmaceutical and life sciences, real-world evidence supports personalized medicine by scrutinizing actual patient data to determine the most effective and safe treatments for particular patient subgroups. As an illustration, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. These newly authorized personalized treatments for 2023 further comprised seven cancer drugs and three for other diseases and conditions. Consequently, the increasing need for personalized medicine is fueling the expansion of the pharmaceutical and life sciences real-world evidence market.
Pharmaceutical And Life Sciences Real World Evidence Market Segment Landscape: Which Areas Lead Development?
The pharmaceutical and life sciences real world evidence market covered in this report is segmented –
1) By Component: Services, Software, Data Sets
2) By Evidence: Descriptive Studies, Analytical Studies, Patient-Reported Outcomes
3) By Real-World Data Sources: Medical Claims, Clinical Trials, Clinical Setting, Patient Powered, Other Real-World Data Sources
4) By Application: Drug Discovery And Development Support, Regulatory Submission And Label Expansion, Market Access And Reimbursement Strategy, Drug Safety And Pharmacovigilance Monitoring, Treatment Decision Support And Clinical Optimization, Comparative Effectiveness And Outcomes Research
5) By End-User: Pharmaceutical And Biopharmaceutical Companies, Healthcare Payers And Providers, Medical Technology Companies, Regulatory And Health Technology Assessment Bodies, Contract Research Organizations And Academic Research Institutions
Subsegments:
1) By Services: Consulting Services, Regulatory Services Or Support, Data Management Services Or Data Integration
2) By Software: RWE Platforms And Dashboards, Predictive Modeling Or Analytics Tools
3) By Data Sets: Electronic Health Records, Patient Registries, Claims And Billing Data
Pharmaceutical And Life Sciences Real World Evidence Market Innovation Trends Shaping Future Development
Leading companies in the pharmaceutical and life sciences real-world evidence market are focusing on creating integrated data-driven platforms. These platforms are designed to enhance the effectiveness of clinical trials, improve patient participation, and support submissions for regulatory approval and health economics. Such integrated data-driven platforms combine diverse real-world data sources, including patient-reported outcomes and information from wearable devices, into organized modules. This approach simplifies processes like recruitment, screening, enrollment, and ongoing patient interactions. For instance, in September 2023, Maxis Clinical Sciences, a US-based boutique consulting firm, introduced a comprehensive real-world evidence solution aimed at supporting patient-focused clinical research and drug development. This platform integrates multiple data streams into pre-configured operational modules, which facilitates faster trial execution and aids in securing regulatory approvals, conducting health economics and outcomes research (HEOR), and developing drug repurposing strategies.
Pharmaceutical And Life Sciences Real World Evidence Market Key Players Shaping Industry Direction
Major companies operating in the pharmaceutical and life sciences real world evidence market are UnitedHealth Group Incorporated, Oracle Corporation, IQVIA Holdings Inc., ICON plc, Parexel International Corporation, Cegedim SA, Veradigm Inc., Tempus AI Inc., Saama Technologies LLC, Komodo Health Inc., Owkin Inc., Trinity Life Sciences LLC, TriNetX LLC, OM1 Inc., HealthVerity Inc., Claritas Rx Inc., PurpleLab Inc., Atropos Health PBC, EvidentIQ Group GmbH, CuriMeta Inc., Medaffcon Oy, and Mahalo Health Inc.
View The Full Pharmaceutical And Life Sciences Real World Evidence Market Report:
Pharmaceutical And Life Sciences Real World Evidence Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the pharmaceutical and life sciences real world evidence market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical and life sciences real world evidence market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model